BENGALURU/HYDERABAD (Reuters) -Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European ...

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ...

Biocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore.

The biosimilars segment, too, will see fresh launches including Bevacizumab in the US, and Semaglutide filings across developed and emerging markets, including India by calendar 2026.

The company said its Board approved a fundraise of up to Rs 4,500 crore and is also evaluating a potential merger of Biocon ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

Today, companies across sectors including Titan Company, L&T, Pidilite Industries, Asian Paints, Britannia Industries, Canara ...

Aviations stocks: Shares of Interglobe Aviation Ltd, the parent company of India's largest airline IndiGo, and SpiceJet will ...

Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025. Cigna has added YESINTEK to its commercial formulary beginning on March 21, 2025 ...

BENGALURU/HYDERABAD May 8 (Reuters) - Indian biopharma firm Biocon's (BION.NS), opens new tab profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar ...